Pilot Trial of Colchicine for Graft Failure in CABG
A Single Center Pilot Trial of Preliminary Effect of Colchicine on Graft Failure in Patients Underwent CABG
Ruijin Hospital
100 participants
Dec 29, 2025
INTERVENTIONAL
Conditions
Summary
The goal of this pilot trial is to to evaluate the preliminary effect of oral colchicine therapy on graft outcomes in patients underwent primary isolated CABG. The main questions it aims to answer is: 1. Whether the oral colchicine therapy may reduce the failure outcome of grafts after CABG. 2. Whether it is feasible to construct a muticenter powered trial to test the superiority hypothesis. Researchers will compare colchicine to none to see if colchicine works. Participants will 1. Take oral colchicine (0.5mg daily) therapy for 12 months after CABG. 2. Clinical follow-up at Month 1, 6, and 12 after CABG. 3. Protocol-driven CCTA at Week 1 and Month 12 after CABG.
Eligibility
Inclusion Criteria4
- Age≥18 years old，
- Any sex，
- Signed informed consent，
- Within 3 days after a successful isolated CABG
Exclusion Criteria4
- Allergy,
- Hematopoietic dysfunction,
- Moderate to severe hepatic dysfunction,
- Moderate to severe renal dysfunction.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Oral Colchicine 0.5mg qd for 1 year
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06802926